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Phosphorylation regulationSignal transducer and activator of transcription 3 (STAT3) is a critical transcriptional factor in a vari-
ety of cellular processes, and is frequently over-activated in a range of human tumors. However, the
processes that regulate STAT3 activation need to be further clariﬁed. With a yeast two-hybrid
screening, we identiﬁed enoyl-CoA hydratase short chain 1 (ECHS1) as a novel STAT3 binding pro-
tein. We further conﬁrmed the interaction between STAT3 and ECHS1 by GST-pull down and co-
immnunoprecipitation. Importantly, we found that ECHS1 speciﬁcally represses STAT3 activity
and negatively regulates the expression of several target genes of STAT3 through inhibiting STAT3
phosphorylation. Therefore, our ﬁndings will provide new insights into the mechanism of STAT3 sig-
naling regulation.
Structured summary of protein interactions:
STAT3 physically interacts with ECHS1 by pull down (View interaction)
STAT3 physically interacts with ECHS1 by two hybrid (View Interaction: 1, 2)
ECHS1 physically interacts with STAT3 by anti tag co immunoprecipitation (View Interaction: 1, 2)
STAT3 physically interacts with ECHS1 by anti bait co immunoprecipitation (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction 705 residue by activated JAK1, phosphorylated STAT3 dimerizesSTAT3 is a member of the STAT transcriptional factor family,
which comprises multiple members, termed STAT1–6. STAT3 was
ﬁrst reported to be activated by interleukin-6 (IL-6) and epidermal
growth factor (EGF), and interacts with an enhancer element in the
promoters of acute phase genes [1,2]. Later studies demonstrated
that STAT3 could be activated by several other cytokines and
growth factors, such as interferon (IFN) and leptin. Binding of li-
gand triggers JAK1-mediated phosphorylation of speciﬁc tyrosine
residues in the cytoplasmic portion of the receptor, then STAT3 is
recruited to the receptor complex and phosphorylated at tyrosineand subsequent translocates into the nucleus and transactivates
target genes [3]. Activation of STAT3 is critical for a variety of cel-
lular processes such as cell proliferation, differentiation, inﬂamma-
tion and immune responses. It has been reported that STAT3 is
constitutively activated in oncogenic transformed cells and various
primary tumors [4]. Constitutive activation of STAT3 induces per-
sistent expression of many target genes, such as BCL2 (an impor-
tant anti-apoptotic factor), BCL2L1 (BCL-2-like protein 1), Cyclin
D1 (a key protein involved in G1-S progression), MMP-2 (matrix
metalloproteinase 2) and so on. Up-regulation of these genes con-
tributes to tumor development or progression through promoting
cell proliferation, tumor angiogenesis and inducing tumor cell
invasion or suppressing anti-tumor immune responses [5–9].
Therefore, STAT3 is considered to be a key player in the pathogen-
esis of diverse human cancers and an ideal target for cancer
therapy.
Enoyl-CoA hydratase short chain 1 (ECHS1) is a key enzyme that
catalyzes the second step in the physiologically important b-oxida-
tion pathway of fatty acid metabolism. Except for its pivotal roles
in regulation of fatty acid metabolism, accumulating literatures
have demonstrated that down-regulation of ECHS1 might be in-
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frequently deleted in metastatic conjunctival melanomas [10]. It
has been reported that ECHS1 expression is also decreased in renal
cell carcinomas and in hepatocellular carcinomas [11,12]. These re-
ports indicated that ECHS1 might play an important role in con-
trolling tumor metastasis or progression. However, it remains
largely unknown about the detailed mechanism that ECHS1 is in-
volved in these processes.
Considering the critical role of STAT3 in tumor development
and progression, regulation of STAT3 signaling has been concerned
more and more. In this study, to further identify potential novel
regulators of STAT3, we performed a yeast two-hybrid screening
for STAT3-interacting proteins from a human mammary cDNA li-
brary, and identiﬁed ECHS1 as a new STAT3 interacting protein.
This interaction was further conﬁrmed by GST pull-down and co-
immnunoprecipitation assays. Importantly, we found that ECHS1
speciﬁcally inhibits STAT3 transcriptional activity induced by IL-6
and EGF. Furthermore, we showed that ECHS1 negatively regulates
IL-6 and EGF induced STAT3 phosphorylation at tyrosine 705 resi-
due, which is the essential molecular event that leads to STAT3
transcriptional activation. Additionally, ECHS1 controlled the
expression of several pro-oncogenic target genes of STAT3, like
MMP-2, BCL2 and Cyclin D1. Taken together, our ﬁndings identiﬁed
a novel STAT3 modulator and revealed a new biological function of
ECHS1.
2. Materials and methods
2.1. Cell culture, transfection and reporter gene analysis
HEK293T and HeLa cells were cultured in DMEM containing 10%
fetal bovine serum at 37 C in a humidiﬁed atmosphere of 5% CO2.
HepG2 cells were maintained in MEM containing 10% fetal bovine
serum plus Sodium Pyruvate (100) (Gibco) and Non-essential
Amino Acid (100) (Gibco). Transfection of plasmids was per-
formed by using Lipofectamine 2000 (Invitrogen) and siRNAs were
transfected by using Lipofectamine RNAiMAX (Invitrogen) follow-
ing the manufacture’s instruction. Luciferase activities were deter-
mined using a Dual-Luciferase Reporter Assay System (Promega).
2.2. Immunoprecipitation, immunoblotting and antibodies
For co-immunoprecipitation experiments, HEK293T cells were
lysed in E1A buffer (50 mM Hepes, pH = 7.5, 250 mM NaCl, 0.1%
Nonidet P-40, 5 mM EDTA) containing certain protease inhibitors.
The whole cell homogenates were incubated with indicated
antibodies and rocked at 4 C for 6 h after the pre-incubating with
protein A/G-Sepharose (Santa Cruz Biotechnology). Immunoprecip-
itates were washed three times and resuspended in 40 ll of 1 SDS
sample buffer, then resolved by SDS–PAGE. All samples for immuno-
blotting assays were prepared in M2 buffer (20 mM Tris–HCl
pH = 7.5, 250 mM NaCl, 0.5% NP-40, 3 mM EDTA, 3 mM EGTA) with
a mixture of protein inhibitors. For endogenous immunoprecipita-
tion experiments, HepG2 cells were untreated or treated with IL-6
(50 ng/ml) for 30 min followed by serum starvation for 16 h, cells
were collected in E1A buffer, then the cell lysates were immunopre-
cipitated by rabbit anti-STAT3 antibody or normal rabbit IgG. Rabbit
anti-ECHS1 (sc-133534) antibody, anti-STAT3 (sc-7179) antibody
andmouse anti-c-Myc (sc-40) antibodywere purchased from Santa
Cruz Biotechnology. Rabbit anti-JAK1 antibody (3332) and anti-
pJAK1 antibody (Tyr1022/1023) (3331) were purchased from cell
signaling technology. Mouse anti-Flag (M2) (F3165) and a-Tubulin
(T5168) monoclonal antibodies were from Sigma. Rabbit anti-
pSTAT3 (Tyr-705) (2236-1) was purchased from Epitomics
Company.2.3. RNA extraction and real-time RT-PCR analysis
HepG2 cells in 6 wells were transfected with ECHS1 siRNA
(40 nM) for 48 h or Myc-ECHS1 (1.5 lg/well) for 24 h, and starved
using MEMwith 0.5% serum for 16–18 h, then stimulated with IL-6
(50 ng/ml) for indicated times. Cell pellets were collected and total
RNA were extracted by Trizol (Invitrogen). The RNA isolation and
data analyses were performed as described in previous study













Comparisons between groups were analyzed by Student’s t test.
A P value of less than 0.05 was considered signiﬁcant.
3. Results
3.1. ECHS1 interacts with STAT3 in yeast
To further explore the regulation and function of STAT3, we per-
formed a yeast two-hybrid screening in attempt to identify new
STAT3 interacting proteins. Since full-length STAT3 leads to the
constitutive activation of the reporter genes, we used two trunca-
tion mutants of STAT3 as baits to screen human mammary cDNA
library. 1–330 aa is the N-terminal of STAT3 containing the Coil–
Coil domain, which was reported to be important for protein–pro-
tein interaction, 575–710 aa contains SH2 domain, which was also
critical to mediate protein association. Finally, 95 positive clones
from 1.6  106 independent transformants were obtained by using
the bait 1–330, and two was found to encode the same protein
ECHS1 with DNA sequencing. The interaction between STAT3 and
ECHS1 was ﬁrst conﬁrmed in yeast system. As shown in Fig. 1A
and B, ECHS1 interacted with full-length STAT3 and the N-termi-
nus (1–330 aa), but not with the SH2 domain (575–710 aa) of
STAT3 or the negative control pGBKT7-LAM.
3.2. ECHS1 interacts with STAT3 in vitro and in vivo
To further conﬁrm the physical interaction between STAT3 and
ECHS1, we performed GST pull-down experiment, and the result
showed that substantial amounts of ECHS1 were pulled down by
GST-STAT3 but not by GST alone (Fig. 1C). To determine whether
STAT3 interacts with ECHS1 in mammalian cells, we carried out a
co-immunoprecipitation experiment in HEK293T cells. Myc-ECHS1
and Flag-STAT3 were co-expressed in HEK293T cells, and then the
cell lysates were immunoprecipitated with an anti-Myc antibody
followed by immunoblotting with an anti-Flag antibody. The result
showed that Flag-STAT3 was precipitated by Myc-ECHS1, but not
Myc-vector (Fig. 1D). Consistently, when the cell lysates were sub-
jected to immunoprecipitation with an anti-Flag antibody, Myc-
ECHS1 was detected in the precipitant (Fig. 1E). To study the pos-
sible physiological signiﬁcance of ECHS1, we investigated the
interaction between endogenous STAT3 and ECHS1 in HepG2 cells.
Fig. 1. ECHS1 interacts with STAT3 in vitro and in vivo. (A) Schematic illustration of full-length human STAT3 protein. The DNA fragment encoding the N-terminal (1–330 aa)
and C-terminal (575–710aa) were fused in-frame with the yeast GAL4 DNA binding domain and used as baits to screen for STAT3 interacting protein in yeast two-hybrid
assay. The numbers refer to the amino acids of STAT3. Interaction is scored as ‘‘+’’ and no interaction as ‘‘’’. (B) Growth of AH109 co-transformed with different GAL4-DBD-
STAT3 and GAL4-AD-ECHS1 constructs on SD medium. Co-transformants were isolated on the SD medium lacking tryptophan and leucine (-Trp-Leu, left plate) or on the SD
medium lacking tryptophan, leucine, adenine, and histidine (-Trp-Leu-Ade-His, right plate). (C) Cell lysates of HEK293T cells transfected with Myc-ECHS1 were incubated
with GST or GST-STAT3, and the bound proteins were detected with anti-Myc antibody. CBB, Coomassie Brilliant Blue staining. (D and E) HEK293T cells were cotransfected
with Flag-STAT3 and Myc-ECHS1 or control vector, and 24 h after transfection, cell lysates were immunoprecipitated with anti-Myc or anti-Flag antibody, then immunoblot
analysis was performed with anti-Flag and anti-Myc antibodies. (F) HepG2 cells were serum starved for 16 h, and then treated or untreated with IL-6 (50 ng/ml) for 30 min,
cell lysates were immunoprecipitated with rabbit normal IgG or rabbit anti-STAT3 antibodies, then western blot was analyzed using anti-ECHS1 and anti-STAT3 antibodies.
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but not rabbit IgG in unstimulated cells, and interestingly, the
amount of immunoprecipitated ECHS1 was signiﬁcantly lower
when the cells were treated with IL-6 for 30 min, suggesting that
interaction between STAT3 and ECHS1 is regulated by the up-
stream signaling. Collectively, these results indicate that ECHS1
associates with STAT3 speciﬁcally in vitro and in vivo.
3.3. ECHS1 inhibits the transcriptional activity of STAT3 induced by IL-
6 and EGF
To investigate the potential biological function of ECHS1 inter-
acting with STAT3, we used reporter luciferase assay to test
whether ECHS1 affects STAT3 transcriptional activity. As shown
in Fig. 2A, HepG2 cells were transfected with pACT-Luc, a luciferase
reporter plasmid containing two STAT3 binding sites, and increas-
ing dose of Myc-ECHS1 constructs. Results showed that ECHS1
inhibits STAT3 transcriptional activity induced by IL-6 in a dose-
dependent manner. Similar results were also obtained in exoge-
nous STAT3 transcriptional activity (Fig. 2B). To further explore
the physiological function of ECHS1 on STAT3 transcriptional activ-ity, endogenous ECHS1 was knocked down by using two different
siRNAs in HepG2 cells and STAT3 transcriptional activity was de-
tected. As expected, ECHS1 depletion augmented the STAT3 tran-
scriptional activity induced by IL-6 (Fig. 2C). To investigate
whether ECHS1 is also involved in STAT3 activation mediated by
other JAK1/STAT3 activators, we examined the effect of ECHS1 on
EGF-mediated STAT3 activation using APRE-Luc, another STAT3-
responsive luciferase reporter. The results showed that ECHS1
overexpression could also suppress EGF-induced STAT3 activation
in HeLa cells (Fig. 2D), and knocking down ECHS1 up-regulated
STAT3 transcriptional activity induced by EGF (Fig. 2E). Consider-
ing the comparable effects and the similar knockdown efﬁciency
of these two different siRNAs (Fig. 2C and E), ECHS1 siRNA #2
was used in most of the ECHS1 RNAi experiments unless indicated
otherwise.
To test the speciﬁcity of ECHS1 on STAT3 activation, we also de-
tected luciferase activity of NF-jB-responsive reporter NF-jB-Luc
and p53-responsive reporter pp53-TA-Luc when ECHS1 or control
plasmids were transfected. As shown in Fig. 2F and G, ECHS1 had
no effect on the transcriptional activity of either NF-jB or p53,
while SOX4 could obviously promote p53 activity as reported
Fig. 2. ECHS1 inhibits STAT3 transcriptional activity induced by IL-6 and EGF. (A) HepG2 cells in a 12-well plate were transiently transfected with pACT-Luc (200 ng/well) and
increasing amounts of Myc-ECHS1 plasmids. 24 h after transfection, cells were starved for 16–18 h in MEM with 0.5% serum and then stimulated with or without IL-6 (50 ng/
ml) for additional 6 h, luciferase activity was measured. Renilla reporter pRL-TK vector were used as an internal control for transfection efﬁciency. The cell lysates were
immunoblotted using anti-Myc and a-Tubulin antibodies. (B) HepG2 cells were transfected and treated the same as in A, except for the addition of Flag-STAT3 (200 ng/well).
(C) HepG2 cells in 12-well plate were transfected with control siRNA or the two different ECHS1 siRNAs (40 nM) (#1 and #2). 48 h after transfection, pACT-Luc (200 ng/well)
and pRL-TK-Luc (20 ng/well) were cotransfected. Another 24 h later, cells were treated with or without IL-6 (50 ng/ml) for 6 h. Luciferase activity was detected and western
blot was performed using anti-ECHS1 and a-Tubulin antibodies. (D and E) HeLa cells were transfected and treated the same as in A and C, except for the APRE-Luc and EGF
treatment. (F) HEK293T cells were cotransfected with NF-jB-Luc (200 ng/well) and indicated dosage of Myc-ECHS1 plasmids. 24 h later, cells were stimulated by TNFa
(10 ng/ml) for 6 h, then luciferase activity and western blot were performed. (G) H460 cells were cotransfected with pp53-TA-Luc (500 ng/well), Myc-vector or increasing
dosage of Myc-SOX4 or Myc-ECHS1 plasmids. 24 h after transfection, luciferase activity was measured and immunoblotting was performed. All the results above are
mean ± S.D. of three independent experiments except G. Statistic analyses were done using Student’s t test between control group and ECHS1 overexpression/knockdown
group after EGF/IL-6 stimulation (⁄P < 0.05 indicate statistically signiﬁcant differences).
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regulator of STAT3 transcriptional activity.
3.4. ECHS1 inhibits STAT3 phosphorylation
Phosphorylation of STAT3 at speciﬁc residues, particularly Tyr-
705, is very important for its activation. To further investigate the
molecular mechanism that ECHS1 regulates STAT3 transcriptional
activity, we next tested whether ECHS1 inhibits STAT3 activity
through regulating its phosphorylation at Tyr-705. To do so, we
examined the kinetics of STAT3 Tyr-705 phosphorylation induced
by IL-6 in HepG2 cells transfected with either Myc-vector orMyc-ECHS1. As shown in Fig. 3A, the amounts of phosphorylated
STAT3 obviously decreased in Myc-ECHS1 overexpressed cells
compared with control cells, while the levels of total STAT3 protein
were similar. To test whether ECHS1 regulate STAT3 phosphoryla-
tion through its kinase JAK1, the phosphorylation level of JAK1 was
also detected. The result showed that JAK1 phosphorylation level
remained unchanged. Conversely, knockdown of ECHS1 in HepG2
cells led to an elevated level of phosphorylated STAT3 (Fig. 3B).
Then we examined the impact of ECHS1 on EGF-induced STAT3
phosphorylation. We found that EGF-induced phosphorylation of
STAT3 at Tyr-705 also decreased in ECHS1-overexpressing cells
compared with control cells (Fig. 3C), and the STAT3 phosphoryla-
Fig. 3. ECHS1 decreases STAT3 tyrosine phosphorylation. (A) HepG2 cells in 6-well plates were transfected with Myc-ECHS1 or Myc-vector (1.5 lg /well). 24 h after
transfection, cells were starved for 16 h in MEM with 0.5% serum and stimulated by IL-6 (50 ng/ml) for 0–120 min, then the total cell lysates were immunoblotted using anti-
pSTAT3 (Tyr-705), anti-STAT3, anti-pJAK1, anti-JAK1, anti-Myc and a-Tubulin antibodies. (B) HepG2 cells were transfected with ECHS1 siRNA (#2) or control siRNA (40nM),
48 h after transfection, cells were starved for 16 h and stimulated by IL-6. Immunoblotting were analyzed with the antibodies as indicated. (C and D) HeLa cells were
transfected and treated the same as in A and B, except that cells were treated with EGF at indicated times.
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gesting that ECHS1-mediated suppression of STAT3 phosphoryla-
tion is not restricted to a particular stimulation. Taken together,
these results suggest that ECHS1 inhibits STAT3 transcriptional
activation through attenuating its phosphorylation.
3.5. ECHS1 negatively regulates expression of STAT3 target genes
Constitutive activation of STAT3 contributes to tumor develop-
ment or progression mainly through regulating target genes that
involving in promoting cell proliferation, inhibiting apoptosis or
inducing cancer cell metastasis. To clarify the roles of ECHS1 in
the process of STAT3 promoting tumorigenesis, we examined the
effect of ECHS1 on the expression of several STAT3 target genes.
We measured the expression of MMP-2, BCL2L1, BCL2 and Cyclin
D1 induced by IL-6 by real time RT-PCR in ECHS1-overexpressing
or knockdown HepG2 cells. As shown in Fig. 4A, overexpression
of ECHS1 led to reduced MMP-2, BCL2L1, BCL2 and Cyclin D1
mRNA expression, and depletion of ECHS1 caused up-regulated
expression of these genes (Fig. 4B). Therefore, these results indicate
that ECHS1 might play a key role in regulating the expression of
STAT3 target genes.
4. Discussion
As one of the most important transcriptional factors involved in
tumorigenesis or tumor progression, STAT3 has been studied for
decades. Despite rapid progress in elucidating the molecular mech-
anisms of activation of JAK1/STAT3 pathway, the processes that
regulate JAK1/STAT3 deactivation are still largely unknown. Sev-
eral lines of evidences have shown that JAK1/STAT3 signaling path-
way could be modulated at multiple steps through different
mechanisms. Protein tyrosine phosphatases (PTP), such as SHP1,
SHP2, CD45, PTP-1b, negatively regulate JAK1/STAT3 pathway by
dephosphorylating cytokine receptors, JAKs, or some other essen-
tial pathway component [15,16]. SOCS proteins are another groupof critical inhibitors of JAK1/STAT3 signaling. Distinct SOCS family
members regulate cytokine signaling through several different
mechanisms, including competitively binding to STATs members,
inhibiting JAKs catalytic activity [17,18] and so on. Our recent
study has shown that CUE domain containing 2 (CUEDC2) speciﬁ-
cally interacts with SOCS3 and acts as a novel SOCS3 co-operator
required for inhibition of JAK1/STAT3 signalling [19]. Except for
the PTP and SOCS family inhibitors, STAT3 is reported to be regu-
lated by some suppressors directly binding to STAT3, like PIAS3
[20], GRIM-19, Daxx and LMW-DSP2 [21–23]. Inhibition of STAT3
by these suppressors is committed either through blocking of
STATs-DNA binding, prevention of their nuclear import, or through
undeﬁned mechanisms. In this study, we found that ECHS1 inhibits
the transcriptional activation of STAT3 through direct interaction.
We demonstrate that ECHS1 suppresses STAT3 phosphorylation
without altering JAK1 phosphorylation, suggesting that inhibition
of ECHS1 on STAT3 activity might not be achieved by regulating
JAK1 activity. It is likely that ECHS1 suppresses JAK1-mediated
STAT3 phosphorylation through allosteric interaction. This hypoth-
esis will be investigated by further experiments.
ECHS1 belongs to the low homology hydratase/isomerase en-
zyme superfamily and is responsible for catalyzing the second step
in the physiologically important b-oxidation pathway of fatty acid
metabolism. Evidence has demonstrated that ECHS1 catalyzes the
hydration of a,b-unsaturated enoyl-CoA thioesters to the corre-
sponding b-hydroxybutyryl-CoA thioesters [24,25]. Down regula-
tion of ECHS1 was detected both in rat models and in patients
with simple steatosis. Knocking down of ECHS1 by small interfer-
ing RNA (siRNA) signiﬁcantly exacerbated lipid accumulation in
hepatocytes induced by free fatty acid (FFA) [26,27]. Recently,
ECHS1 is reported to be involved in other biological processes or
diseases. For example, expression of ECHS1 was found to be altered
during corpus luteum (CL) maintenance and most likely involved
in mechanisms allowing the CL to produce progesterone during
early pregnancy [28]. ECHS1 also participates in VPA biotransfor-
mation [29]. These evidences suggest that ECHS1 is a multifunc-
Fig. 4. ECHS1 affects STAT3 target genes expression. (A) HepG2 cells in 6-well plate were transfected with Myc-Vector or Myc-ECHS1(1.5 lg/well), 24 h after transfection,
cells were starved for 16–18 h in MEM with 0.5% serum, and stimulated by IL-6 (50 ng/ml) for different times. One half of cells were lysed in M2 buffer and immunoblotted
using anti-Myc and a-Tubulin antibodies, and another half of cells were determined the relative mRNA expression levels of MMP-2, BCL2L1, BCL2 and Cyclin D1 by real-time
RT-PCR. Samples were respectively harvested at 6 h (MMP-2) or 24 h (BCL2L1, BCL2 and Cyclin D1) after IL-6 stimulation as described in Materials and methods. (B) HepG2
cells were transfected with ECHS1 siRNA (#2) or control siRNA(40 nM), 48 h after transfection, cells were starved and treated with IL-6 as in A. All the results above are
mean ± S.D. of three independent experiments Statistic analyses were done using Student’s t test between control group and ECHS1 overexpression/knockdown group after
IL-6 stimulation. (⁄P < 0.05 indicate statistically signiﬁcant differences).
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uncovered.
Recently, a large body of literatures has demonstrated that
ECHS1 was down-regulated in a variety of cancers. Liu et al. re-
ported that ECHS1 was not only down-regulated in MCF-7 cells
but also in other carcinoma cells, such as MDA-MB-231 (breast
adenocarcinoma cell line), T47D (breast ductal carcinoma cell line),
DU145 (prostate carcinoma cell line), HCT-8 (colon adenocarcino-
macell line) and SKOV-3 (ovarian adenocarcinoma cell line) [30].
In metastatic conjunctival melanomas, ECHS1 was frequently de-
leted [10]. It has also been reported that ECHS1 expression de-
creased in renal cell carcinomas and in hepatocellular carcinomas
[11,12]. These ﬁndings suggested that down regulation of ECHS1
might contribute to tumorigenesis or tumor metastasis. However,
little is known about the function of ECHS1 in these processes. In
this study, we found that ECHS1 binds to STAT3, negatively regu-
lates STAT3 activity and inhibits expression of its critical target
genes which play important roles in tumor metastasis and cell
growth. Thus, down-regulation of ECHS1 might lead to constitutive
STAT3 activation and result in tumor development or progression.
Our ﬁndings provide one possibility to explain the signiﬁcance of
ECHS1 down regulation in multiple tumor types.
In conclusion, we identiﬁed ECHS1 as a novel STAT3 binding
protein. Further study demonstrated that ECHS1 inhibits STAT3
phosphorylation, transcriptional activity and the subsequent target
genes expression. Therefore, our work not only identiﬁed a novel
STAT3 inhibitor but also provided important insight into the criti-
cal roles of ECHS1 in the intricate STAT3 signal transduction net-
work, although a more detailed mechanism that ECHS1 regulates
STAT3 need to be further studied.
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